Migraine
Conditions
Brief summary
This is a double-blind, placebo-controlled, randomized, multi-center study. Subjects agreeing to participate in the study and meet the entry criteria assessed at the screening visit, will begin a 28 day baseline period to confirm their diagnosis, as well as establish baseline migraine characteristics. During this baseline period, subjects will continue treating their migraines as usual, simply recording the information in a daily headache diary. Subjects who, after completing the baseline, continue to meet entrance criteria will be eligible to enter into the treatment phase and be randomized according to the Clinvest generated randomization schedule. Approximately 142 subjects (71 subjects per arm) will be randomized and enter the treatment phase receiving MLD10 or placebo in a 1:1 design at 6 United States sites. Diary assessments will collect study medication adherence, pain severity, headache symptoms, acute medication usage, and unusual symptoms. Serum samples will be collected and analyzed for ionized magnesium, electrolytes, and creatinine.
Detailed description
This is a multi-center, double-blind, randomized, placebo-controlled, parallel study of MLD10 for the prevention of migraine headache. The study population will consist of approximately 142 male and female subjects between 18 and 65 years of age with frequent episodic migraine as defined by International Classification of Headache Disorders-3beta criteria. Two MLD10 (243 mg (milligrams) of elemental magnesium) or placebo caplets will be taken twice daily for a total daily dose of 486 mg. VISIT 1 - SCREENING The following will be completed at Visit 1: 1. Obtain written Informed Consent. The informed consent will be obtained in accordance with Good Clinical Practices (GCP) and all applicable regulatory requirements from each subject prior to participation in the study. 2. Verify Inclusion/Exclusion Criteria. Subjects will meet all the inclusion and none of the exclusion criteria. 3. Obtain demographics (race, ethnicity, sex, date of birth) 4. Obtain medical, medication, and headache history. Data collected will include medical history and diagnoses, age at onset of migraine and other pertinent migraine/headache history, history of acute and prophylactic headache medications within the past 30 days, and history of other recent/concomitant medications. 5. Obtain date of last menstrual cycle and perform urine pregnancy test, if appropriate. Results of the pregnancy test must be negative to continue in study. 6. Perform physical and neurological examinations. 7. Measure vital signs (height, weight, resting heart rate, and blood pressure). 8. Review Baseline Headache Diary. Subjects will be instructed to complete a daily online headache diary. Assessments to be captured are start/stop time, severity, associated symptoms, use of rescue medications, and unusual symptoms. 9. Administer Columbia-Suicide Severity Rating Scale (C-SSRS). 10. Schedule Visit 2. VISIT 2 - RANDOMIZATION 1. Verify Inclusion/Exclusion Criteria. Subjects must continue to meet all inclusion (including ≥ 3 days of migraine during baseline) and none of the exclusion criteria. 2. Perform urine pregnancy test, if appropriate. Results of the pregnancy test must be negative to continue in study. 3. Measure vital signs (weight, resting heart rate, and blood pressure). 4. Record any changes to concomitant medications. 5. Record any Serious Adverse Events (SAE) since signing the Informed Consent. 6. Review Baseline Headache Diary for completeness and continuing eligibility. 7. Randomize subject 8. Review Month 1 Headache Diary instructions (same instructions as those discussed for Baseline Headache Diary). 9. Dispense Month 1 study medication. Subjects will be instructed how to take study medication, prohibited medications/foods, dosage limitations of study medication, and storage requirements. Subjects will be instructed to return all used/partially used/unused study medication at next office visit and medications reconciliation will be performed to ensure a compliance of at least 80%. Subjects not complying at an 80% level will be withdrawn, unless otherwise approved by the Sponsor and/or Clinvest. (Estimated to be \< 10%) 10. Administer C-SSRS. 11. Administer MIDAS. 12. Collect serum samples for electrolytes, creatinine, and ionized Mg. 13. Schedule Visit 3. VISIT 3 - END OF TREATMENT PERIOD MONTH 1 1. Record any changes to concomitant medications. 2. Record any Non-Serious Adverse Events (NSAE) and/or SAEs. 3. Perform urine pregnancy test, if appropriate. Results of the pregnancy test must be negative to continue in study. 4. Measure vital signs (weight, resting heart rate, and blood pressure). 5. Review Month 1 Headache Diary for completeness. 6. Review instructions for Month 2 Headache Diary (same instructions as those discussed for Month 1 Headache Diary). 7. Collect Month 1 unused study medication and used packaging. Confirm 85% compliance of medication usage per study protocol. 8. Dispense Month 2 study medication and review the dosage limitations of study medication, storage requirements, and to return all used/partially used/unused study medication at next office visit. 9. Perform drug accountability. 10. Administer C-SSRS. 11. Collect serum samples for electrolytes, creatinine, and ionized Mg. 12. Schedule Visit 4. VISIT 4 - END OF TREATMENT PERIOD MONTH 2 1. Record any changes to concomitant medications. 2. Record any NSAEs/SAEs. 3. Perform urine pregnancy test, if appropriate. Results of the pregnancy test must be negative to continue in study. 4. Measure vital signs (weight, resting heart rate, and blood pressure). 5. Review Month 2 Headache Diary for completeness. 6. Review instructions for Month 3 Headache Diary (same instructions as those discussed for Month 2 Headache Diary). 7. Collect Month 2 unused study medication and used packaging. Confirm 85% compliance for medication usage per study protocol. 8. Dispense Month 3 study medication and review the dosage limitations of study medication, storage requirements, and to return all used/partially used/unused study medication at next office visit. 9. Perform drug accountability. 10. Administer C-SSRS. 11. Collect serum samples for electrolytes, creatinine, and ionized Mg. 12. Schedule Visit 5. VISIT 5 - END OF TREATMENT PERIOD MONTH 3 1. Record any changes to concomitant medications. 2. Record any NSAEs/SAEs. 3. Perform urine pregnancy test, if appropriate. 4. Measure vital signs (weight, resting heart rate, and blood pressure) 5. Perform physical/neurological examinations. 6. Collect Month 4 unused study medication and used packaging. 7. Perform drug accountability. 8. Administer SGIC & complete PGIC. 9. Administer MIDAS. 10. Administer C-SSRS. 11. Collect serum samples for electrolytes, creatinine, and ionized Mg. 12. Exit subject.
Interventions
DRUGMLD10
DRUGPlacebo
Sponsors
Clinvest
Pharmalyte Solutions LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. male or female, in otherwise good health, 18 to 65 years of age. 2. history of frequent episodic migraine (3-14 migraine days per month) (with or without aura) according to the International Classification of Headache Disorders-3beta for at least 3 months. 3. onset of migraine before age 50. 4. stable history of migraine at least 3 months prior to screening. 5. not currently taking a migraine preventive or has been taking preventive for at least 30 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period. 6. if female of childbearing potential, has a negative urine pregnancy test at Visits 1-5 and uses, or agrees to use, for the duration of the study, a medically acceptable form of contraception as listed: * complete abstinence from intercourse from 2 weeks prior to administration of study drug, throughout the study, and for 7 days after completion or premature discontinuation from the study; surgically sterile (hysterectomy or tubal ligation or otherwise incapable of pregnancy); sterilization of male partner when in a monogamous relationship; intrauterine device with published data showing lowest expected failure rate is less than 1% per year; double barrier method (i.e., 2 physical barriers OR 1 physical barrier plus spermicide) for a least 1 month prior to Visit 1 and throughout study; or hormonal contraceptives for at least 3 months prior to Visit 1 and throughout study. 7. completion of online diary must be ≥ 80% compliance, unless otherwise approved by the Sponsor and/or Clinvest.
Exclusion criteria
1. unable to understand the study requirements, the informed consent, or complete headache records as required per protocol. 2. pregnant, actively trying to become pregnant, or breast-feeding. 3. diagnosed with International Classification of Headache Disorders-3beta criteria for Chronic Migraine within 3 months prior to screening, at the time of screening, and/or during the baseline period. 4. experienced the following migraine variants: basilar migraine, aura without headache, familial hemiplegic migraine, complicated migraine, ophthalmoplegic migraine and retinal migraine within the last year. 5. history of medication overuse headache (MOH) (Appendix II) in the 3 months prior to study enrollment or during the baseline phase. 6. history of medication overuse (MO) of ergotamines, triptans, opioids, analgesics, NSAIDS and combination therapies, as defined by ICHD-3beta criteria and/or MO during baseline period. 7. history of substance abuse and/or dependence, in the opinion of the Investigator. 8. history of impaired renal function that, in the investigator's opinion, contraindicates participation in this study. 9. unstable neurological condition or a significantly abnormal neurological examination with focal signs or signs of increased intracranial pressure. 10. suffers from a serious illness, or an unstable medical condition, one that could require hospitalization, or could increase the risk of adverse events. 11. has significant risk of suicide, defined as a yes answer to any of the following questions on the Columbia-Suicide Severity Rating Scale (C-SSRS), either at the screening visit (when assessing the prior 12 months) or at visit 2 (when assessing time since the screening visit): 1. Questions 4 or 5 on the suicidal ideation section 2. Any question on any item in the suicidal behavior section 12. any psychiatric disorder with psychotic features, and/or any other psychiatric disorder not stable or well controlled, that would interfere in their ability to complete study activities. 13. hypersensitivity, intolerance, or contraindication to the use of magnesium L-lactate dehydrate or any of its components. 14. received any investigational agents within 30 days prior to Visit 1. 15. plans to participate in another clinical study at any time during this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Migraine Headache Days | Day 1(Screening) - Day 116 (Visit 5 End of Study) | Comparison of the mean change from baseline in the frequency of migraine headache days per 28-day period ending with the cessation of treatment period month 3 in subjects treated with MLD10 versus placebo. A migraine headache day will be defined as a calendar day (00:00 to 23:59) with 4 or more hours of migraine headache, fulfilling International Classification of Headache Disorders-3beta criteria, and/or any headache of any duration with the use of migraine-specific acute medications(s) (i.e. ergot alkaloids, ergot combinations, opioids, triptans, combination analgesics \[simple analgesics combined with opioids or barbiturate with or without caffeine\]). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Headache Duration | Day 1(Screening) - Day 116 (Visit 5 End of Study) | Change from baseline (28 day period) in the total cumulative minutes of headache during each 28-day treatment period month 1, 2, & 3 in subjects treated with MLD10 versus placebo. All headaches and/or migraines will be including in this outcome analysis. |
| Pain Severity | Day 1(Screening) - Day 116 (Visit 5 End of Study) | Change from baseline (28 day period) in the average pain severity at time of onset compared to each 28-day treatment period month 1, 2, & 3 in subjects treated with MLD10 versus placebo. Headache pain severity was measured on a scale 1 = Mild, 2 = Moderate, 3 = Severe. |
| Acute Medication Usage | Day 1(Screening) - Day 116 (Visit 5 End of Study) | Change from baseline (28 day period) in the total number of acute headache pain medications used during each 28 day treatment period month 1, 2, & 3 in subjects treated with MLD10 versus placebo. |
| Headache Days | Day 1(Screening) - Day 116 (Visit 5 End of Study) | Comparison of the change from baseline of subjects treated with MLD10 versus placebo in the frequency of headache days during the 3 month treatment period. A headache day will be defined as any day not classified as a migraine day, but recorded headache of any severity and/or duration. |
| Subject Global Impression of Change (SGIC) | Day 116 (Visit 5 End of Study) | Comparison of SGIC at Visit 5 in subjects treated with MLD10 versus placebo. Global impression of change rated by the subject will be assessed using a 7-point Likert scale ranging from -3 to 3 with -3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = no change, 1 = minimally improved, 2 = much improved, 3 = very much improved. |
| Physician Global Impression of Change (PGIC) | Day 116 (Visit 5 End of Study) | Comparison of PGIC at Visit 5 in subjects treated with MLD10 versus placebo. The PGIC will be an impression of change rated by the investigator using a 7-point Likert scale ranging from -3 to 3 with -3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = no change, 1 = minimally improved, 2 = much improved, 3 = very much improved. |
| Migraine Disability Assessment Scale (MIDAS) | Day 29 (Randomization) & Day 116 (Visit 5 End of Study) | Change from Visit 2 to Visit 5 in the total MIDAS score in subjects treated with MLD10 versus placebo. The MIDAS test determines how severely migraines affect daily functioning. The responses of a variety of questions will be scored according to the questionnaire's scoring guide. A total score will be calculated ranging from 0-93. A score of 0-5 indicates little or no disability, 6-10 mild disability, 11-20, moderate disability, 21+ severe disability. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| MLD10 All study participants randomized to MLD10 arm | 80 |
| Placebo All study participants randomized to Placebo arm | 77 |
| Total | 157 |
Baseline characteristics
| Characteristic | Placebo | Total | MLD10 |
|---|---|---|---|
| Age, Continuous | 44.74 years STANDARD_DEVIATION 11.41 | 43.01 years STANDARD_DEVIATION 12.18 | 41.35 years STANDARD_DEVIATION 12.72 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 6 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 74 Participants | 151 Participants | 77 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 3 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 16 Participants | 21 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 5 Participants | 5 Participants |
| Race (NIH/OMB) White | 58 Participants | 126 Participants | 68 Participants |
| Sex: Female, Male Female | 69 Participants | 140 Participants | 71 Participants |
| Sex: Female, Male Male | 8 Participants | 17 Participants | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 80 | 0 / 77 |
| other Total, other adverse events | 17 / 80 | 15 / 77 |
| serious Total, serious adverse events | 1 / 80 | 1 / 77 |
Outcome results
Primary
Migraine Headache Days
Comparison of the mean change from baseline in the frequency of migraine headache days per 28-day period ending with the cessation of treatment period month 3 in subjects treated with MLD10 versus placebo. A migraine headache day will be defined as a calendar day (00:00 to 23:59) with 4 or more hours of migraine headache, fulfilling International Classification of Headache Disorders-3beta criteria, and/or any headache of any duration with the use of migraine-specific acute medications(s) (i.e. ergot alkaloids, ergot combinations, opioids, triptans, combination analgesics \[simple analgesics combined with opioids or barbiturate with or without caffeine\]).
Time frame: Day 1(Screening) - Day 116 (Visit 5 End of Study)
Population: The modified intent-to-treat (mITT) population included all randomized subjects who received at least one dose of study drug and obtained at least one endpoint measurement after treating. The mITT population excluded 7 subjects from the MLD10 arm and 6 participants from the Placebo arm. Total mITT analysis population: MLD10 = 73, Placebo = 71.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MLD10 | Migraine Headache Days | Baseline | 7.12 Days | Standard Deviation 2.94 |
| MLD10 | Migraine Headache Days | Treatment Period 3 | 5.53 Days | Standard Deviation 4.43 |
| Placebo | Migraine Headache Days | Baseline | 6.92 Days | Standard Deviation 2.71 |
| Placebo | Migraine Headache Days | Treatment Period 3 | 4.79 Days | Standard Deviation 4.2 |
Secondary
Acute Medication Usage
Change from baseline (28 day period) in the total number of acute headache pain medications used during each 28 day treatment period month 1, 2, & 3 in subjects treated with MLD10 versus placebo.
Time frame: Day 1(Screening) - Day 116 (Visit 5 End of Study)
Population: The modified intent-to-treat (mITT) population included all randomized subjects who received at least one dose of study drug and obtained at least one endpoint measurement after treating. The mITT population excluded 7 subjects from the MLD10 arm and 6 participants from the Placebo arm. Total mITT analysis population: MLD10 = 73, Placebo = 71.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MLD10 | Acute Medication Usage | Treatment Period 2 | 9.12 Medications | Standard Deviation 7.08 |
| MLD10 | Acute Medication Usage | Treatment Period 1 | 9.74 Medications | Standard Deviation 8.15 |
| MLD10 | Acute Medication Usage | Treatment Period 3 | 9.18 Medications | Standard Deviation 8.4 |
| MLD10 | Acute Medication Usage | Baseline | 11.67 Medications | Standard Deviation 7.64 |
| Placebo | Acute Medication Usage | Treatment Period 3 | 8.25 Medications | Standard Deviation 8.67 |
| Placebo | Acute Medication Usage | Treatment Period 1 | 8.13 Medications | Standard Deviation 6.23 |
| Placebo | Acute Medication Usage | Treatment Period 2 | 8.61 Medications | Standard Deviation 8.38 |
| Placebo | Acute Medication Usage | Baseline | 11.08 Medications | Standard Deviation 6.1 |
Secondary
Headache Days
Comparison of the change from baseline of subjects treated with MLD10 versus placebo in the frequency of headache days during the 3 month treatment period. A headache day will be defined as any day not classified as a migraine day, but recorded headache of any severity and/or duration.
Time frame: Day 1(Screening) - Day 116 (Visit 5 End of Study)
Population: The modified intent-to-treat (mITT) population included all randomized subjects who received at least one dose of study drug and obtained at least one endpoint measurement after treating. The mITT population excluded 7 subjects from the MLD10 arm and 6 participants from the Placebo arm. Total mITT analysis population: MLD10 = 73, Placebo = 71.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MLD10 | Headache Days | Baseline | 9.01 Days | Standard Deviation 3.16 |
| MLD10 | Headache Days | Treatment Period 3 | 6.89 Days | Standard Deviation 5.36 |
| Placebo | Headache Days | Baseline | 9.20 Days | Standard Deviation 3.7 |
| Placebo | Headache Days | Treatment Period 3 | 6.25 Days | Standard Deviation 4.81 |
Secondary
Headache Duration
Change from baseline (28 day period) in the total cumulative minutes of headache during each 28-day treatment period month 1, 2, & 3 in subjects treated with MLD10 versus placebo. All headaches and/or migraines will be including in this outcome analysis.
Time frame: Day 1(Screening) - Day 116 (Visit 5 End of Study)
Population: The modified intent-to-treat (mITT) population included all randomized subjects who received at least one dose of study drug and obtained at least one endpoint measurement after treating. The mITT population excluded 7 subjects from the MLD10 arm and 6 participants from the Placebo arm. Total mITT analysis population: MLD10 = 73, Placebo = 71.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MLD10 | Headache Duration | Baseline | 410.03 Minutes | Standard Deviation 182.26 |
| MLD10 | Headache Duration | Treatment Period 1 | 430.88 Minutes | Standard Deviation 242.35 |
| MLD10 | Headache Duration | Treatment Period 2 | 443.89 Minutes | Standard Deviation 233.6 |
| MLD10 | Headache Duration | Treatment Period 3 | 429.26 Minutes | Standard Deviation 228.59 |
| Placebo | Headache Duration | Treatment Period 3 | 383.70 Minutes | Standard Deviation 204.06 |
| Placebo | Headache Duration | Baseline | 396.48 Minutes | Standard Deviation 166.75 |
| Placebo | Headache Duration | Treatment Period 2 | 364.21 Minutes | Standard Deviation 186.09 |
| Placebo | Headache Duration | Treatment Period 1 | 369.03 Minutes | Standard Deviation 188.78 |
Secondary
Migraine Disability Assessment Scale (MIDAS)
Change from Visit 2 to Visit 5 in the total MIDAS score in subjects treated with MLD10 versus placebo. The MIDAS test determines how severely migraines affect daily functioning. The responses of a variety of questions will be scored according to the questionnaire's scoring guide. A total score will be calculated ranging from 0-93. A score of 0-5 indicates little or no disability, 6-10 mild disability, 11-20, moderate disability, 21+ severe disability.
Time frame: Day 29 (Randomization) & Day 116 (Visit 5 End of Study)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MLD10 | Migraine Disability Assessment Scale (MIDAS) | Visit 2 | 33.94 units on a scale | Standard Deviation 34.56 |
| MLD10 | Migraine Disability Assessment Scale (MIDAS) | Visit 5 | 27.14 units on a scale | Standard Deviation 33.91 |
| Placebo | Migraine Disability Assessment Scale (MIDAS) | Visit 2 | 27.03 units on a scale | Standard Deviation 25.41 |
| Placebo | Migraine Disability Assessment Scale (MIDAS) | Visit 5 | 21.40 units on a scale | Standard Deviation 18.64 |
Secondary
Pain Severity
Change from baseline (28 day period) in the average pain severity at time of onset compared to each 28-day treatment period month 1, 2, & 3 in subjects treated with MLD10 versus placebo. Headache pain severity was measured on a scale 1 = Mild, 2 = Moderate, 3 = Severe.
Time frame: Day 1(Screening) - Day 116 (Visit 5 End of Study)
Population: The modified intent-to-treat (mITT) population included all randomized subjects who received at least one dose of study drug and obtained at least one endpoint measurement after treating. The mITT population excluded 7 subjects from the MLD10 arm and 6 participants from the Placebo arm. Total mITT analysis population: MLD10 = 73, Placebo = 71.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MLD10 | Pain Severity | Baseline | 2.16 units on a scale | Standard Deviation 0.5 |
| MLD10 | Pain Severity | Treatment Period 1 | 2.07 units on a scale | Standard Deviation 0.54 |
| MLD10 | Pain Severity | Treatment Period 2 | 1.99 units on a scale | Standard Deviation 0.54 |
| MLD10 | Pain Severity | Treatment Period 3 | 2.01 units on a scale | Standard Deviation 0.49 |
| Placebo | Pain Severity | Treatment Period 3 | 1.86 units on a scale | Standard Deviation 0.57 |
| Placebo | Pain Severity | Baseline | 2.06 units on a scale | Standard Deviation 0.37 |
| Placebo | Pain Severity | Treatment Period 2 | 1.85 units on a scale | Standard Deviation 0.53 |
| Placebo | Pain Severity | Treatment Period 1 | 1.93 units on a scale | Standard Deviation 0.49 |
Secondary
Physician Global Impression of Change (PGIC)
Comparison of PGIC at Visit 5 in subjects treated with MLD10 versus placebo. The PGIC will be an impression of change rated by the investigator using a 7-point Likert scale ranging from -3 to 3 with -3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = no change, 1 = minimally improved, 2 = much improved, 3 = very much improved.
Time frame: Day 116 (Visit 5 End of Study)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MLD10 | Physician Global Impression of Change (PGIC) | 1.07 units on a scale | Standard Deviation 1.09 |
| Placebo | Physician Global Impression of Change (PGIC) | 1.06 units on a scale | Standard Deviation 1.12 |
Secondary
Subject Global Impression of Change (SGIC)
Comparison of SGIC at Visit 5 in subjects treated with MLD10 versus placebo. Global impression of change rated by the subject will be assessed using a 7-point Likert scale ranging from -3 to 3 with -3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = no change, 1 = minimally improved, 2 = much improved, 3 = very much improved.
Time frame: Day 116 (Visit 5 End of Study)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MLD10 | Subject Global Impression of Change (SGIC) | 1.25 units on a scale | Standard Deviation 0.987 |
| Placebo | Subject Global Impression of Change (SGIC) | 1.10 units on a scale | Standard Deviation 1.23 |